Celator Pharmaceuticals, Inc. Reaches 50% Enrollment For CPX-351 Phase 3 Study
1/9/2014 9:44:16 AM
EWING, N.J., Jan. 9, 2014 (GLOBE NEWSWIRE) -- Celator Pharmaceuticals, Inc. (Nasdaq:CPXX), a pharmaceutical company developing new and more effective therapies to treat cancer, today announced that the Company's Phase 3 clinical study comparing CPX-351 (cytarabine:daunorubicin) Liposome Injection versus the conventional cytarabine and daunorubicin treatment regimen (commonly referred to as 7+3) as first-line therapy in older patients with high-risk (secondary) acute myeloid leukemia (AML) has reached 50% of the study's planned enrollment of 300 patients.
Help employers find you! Check out all the jobs and post your resume.